Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection (Eveotox) Compared With a Single Treatment of Botox and Placebo,and Repeated Treatment of Eveotox in Moderate to Severe Glabellar Lines

NCT06937944 is registered in ClinicalTrials.gov with JHM BioPharma (Tonghua) Co. , Ltd. as lead sponsor.

NCT NCT06937944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection (Eveotox) Compared With a Single Treatment of Botox and Placebo,and Repeated Treatment of Eveotox in Moderate to Severe Glabellar Lines
Lead sponsor
JHM BioPharma (Tonghua) Co. , Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
April 30, 2025
Completion date
September 30, 2026
Enrollment
669 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe glabellar lines